Glenmark Cuts Price of Breast Cancer Drug Trastuzumab; 440 mg Vial will now be Priced at Rs 15,749

Pharma Glenmark Pharmaceuticals, a major pharmaceutical company, announced a price drop for Trastuzumab. The medicine is used to treat HER2-positive breast cancer and is known as 'Trumab' in India. Trumab's 440 mg vial will now cost Rs 15,749. The company stated that with the price reduction, the medicine is now the most economical choice offered in the country's market.

Trastuzumab, a monoclonal antibody, has long been the standard therapeutic option for HER2-positive breast cancer. Despite the fact that the expense of Trastuzumab treatment has been a major obstacle for many patients in India, the medicine has been in use for many years. "At Glenmark, we believe that everyone deserves access to quality healthcare, regardless of their financial situation," said Alok Malik, Executive Vice President and Head of India Formulations, Glenmark Pharmaceuticals Ltd., in announcing the company's move to reduce the cost of its life-saving drug Trumab.

This would not only improve access, but will also give hope to more than 75% of self-paying HER2-positive breast cancer patients in India." HER2, also known as human epidermal growth factor receptor 2, is overexpressed in all breast cells and is tested for. Cell growth and division are regulated by HER2 proteins, which are receptors. Breast cancer that has been found to be HER2-positive has a propensity to grow more quickly, disseminate, and recur. This protein aids the growth and spread of cancer cells. This protein helps cancer cells grow and spread. Trastuzumab works by binding to the HER2 protein and blocking its activity. According to the GLOBOCAN 2020 report, breast cancer is the most commonly diagnosed cancer in India, accounting for 13.5 per cent of all cases, with an estimated 1.78 lakh new cases diagnosed each year and a 5-year prevalence of 4.5 lakh cases.